Physician profile
Michael Yu
NPI 1104816131
$42,502.50
in general payments reported to CMS, 2019-2025
37 companies · $5,483 in 2025
The $5,483 reported for 2025 was more than what 91% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,609 · 2020: $2,239 · 2021: $5,657 · 2022: $11K · 2023: $9,011 · 2024: $3,386 · 2025: $5,483.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Grant: $7,250 · Food and Beverage: $6,214 · Travel and Lodging: $4,417.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Grant | $7,250.00 |
| Food and Beverage | $6,213.59 |
| Travel and Lodging | $4,416.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coloplast Corp | $9,956.38 | 2019-2025 | Isiris Astent Removal Device |
| Medtronic, INC. | $9,275.08 | 2021-2025 | Altaviva, Interstim |
| Axonics, INC. | $4,712.71 | 2020-2024 | Axonics |
| Teleflex LLC | $3,716.46 | 2021-2024 | Urolift |
| Boston Scientific Corporation | $3,325.19 | 2019-2025 | Lithovue, Lumenis Pulse 120h, Axonics |
| Calyxo, INC. | $3,280.87 | 2022-2025 | Cvac Aspiration System |
| Procept Biorobotics Corporation | $2,349.79 | 2020-2025 | Aquabeam Robotic System, Aquabeam System |
| Neotract INC. | $2,158.04 | 2019-2020 | |
| Medtronic USA, INC. | $1,887.55 | 2019-2020 | |
| Ferring Pharmaceuticals INC. | $235.92 | 2025 | Adstiladrin |
| Stryker Corporation | $213.90 | 2020 | |
| Lumenis, INC | $181.70 | 2021 | |
| Myovant Sciences INC. | $173.84 | 2021 | |
| Astellas Pharma US INC | $139.30 | 2019 | |
| Janssen Biotech, INC. | $119.46 | 2019-2021 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bluewind Medical | $89.79 | 2025 | Revi |
| Olympus America INC. | $75.04 | 2023 | Itind System |
| Bayer Healthcare Pharmaceuticals INC. | $71.21 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $61.29 | 2021-2022 | |
| Rochester Medical Corporation | $54.53 | 2019-2020 | |
| Tolmar Pharmaceuticals, INC. | $47.34 | 2019 | |
| Laborie Medical Technologies Corp. | $43.39 | 2023-2024 | Optilume Bph Drug Coated Balloon Catheter |
| Abbvie INC. | $33.37 | 2019 | |
| Sun Pharmaceutical Industries INC. | $33.08 | 2019 | |
| Janssen Scientific Affairs, LLC | $32.93 | 2019 | |
| Foundation Medicine, INC. | $32.50 | 2019 | |
| Antares Pharma, INC. | $29.32 | 2019 | |
| Ethicon US, LLC | $26.39 | 2019 | |
| Abbott Laboratories | $26.23 | 2022 | |
| Innovation Technologies INC | $17.73 | 2024 | Irrisept |
| Travere Therapeutics, INC. | $17.17 | 2021-2022 | |
| Cook Medical LLC | $16.58 | 2024 | Zilver Ptx |
| 180 Medical, INC. | $16.07 | 2019 | |
| Genzyme Corporation | $14.92 | 2019 | |
| Amgen INC. | $14.54 | 2019 | |
| Endo Pharmaceuticals INC. | $11.63 | 2019 | |
| Bard Access Systems, INC. | $11.26 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Yu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.